Indication for Sunvozertinib
Sunvozertinib is indicated for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy, and has now demonstrated superior efficacy as first-line therapy compared to chemotherapy. 1
FDA-Approved Indication
The drug received accelerated approval in August 2023 for previously treated patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who have progressed on or after platinum-based chemotherapy, or who are intolerant to such treatment 2. This approval was based on objective response rates and duration of response from single-arm phase 2 trials 3, 4.
Emerging First-Line Use
The phase 3 WU-KONG28 trial has now established sunvozertinib as superior to chemotherapy in the first-line setting, demonstrating:
- Median progression-free survival of 10.3 months versus 7.5 months with carboplatin-pemetrexed (HR 0.65, P<0.001) 1
- Objective response rate of 58.9% versus 31.1% with chemotherapy 1
- Median duration of response of 11.2 months versus 7.1 months 1
This represents a paradigm shift for EGFR exon 20 insertion NSCLC, a molecular subset that historically showed poor response to conventional EGFR TKIs and relied primarily on platinum-doublet chemotherapy 5.
Dosing Considerations
Two doses have regulatory approval in different regions:
- 200 mg daily (FDA-approved in the United States based on WU-KONG1B) 4
- 300 mg daily (approved in China based on WU-KONG6) 3
The 300 mg dose showed higher response rates in patients with baseline brain metastases (52.4% vs 28.6%) and longer duration of response (13.8 vs 11.1 months), but with increased grade ≥3 adverse events, particularly diarrhea (18% vs 2.2%) 4.
Clinical Context
EGFR exon 20 insertions represent 1-3% of EGFR mutations in NSCLC and have been notoriously difficult to treat due to altered kinase domain conformation causing resistance to earlier-generation EGFR TKIs 5. Sunvozertinib addresses this through selective targeting of exon 20 insertion variants while sparing wild-type EGFR, reducing dose-limiting toxicities 5.
Key Safety Profile
The most common grade ≥3 adverse events include:
- Increased creatine phosphokinase (12-18% depending on dose) 4
- Diarrhea (2-18% depending on dose) 4
- Anemia (4-6%) 4
No treatment-related deaths were reported in the first-line trial 1.
Important Caveats
Despite FDA approval, sunvozertinib remains largely inaccessible to patients in the United States due to availability challenges 6. This creates a significant gap between regulatory approval and real-world access for patients who could benefit from this targeted therapy.